Medication development for the treatment of cocaine dependence
Subtitle: issues in clinical efficacy trials
By: editors, Betty Tai, Nora Chiang, Peter Bridge.
Contributors: Tai, Betty.; Chiang, C. Nora.; Bridge, Peter.; National Institute on Drug Abuse. Office of Science Policy and Communications.
Series: NIDA research monograph -- 175.; NIH publication -- no. 98-4125.
Publisher: U.S. Dept. of Health and Human Services, National Institutes of Health, National Institute on Drug Abuse, Office of Science Policy and Communications; Supt. of Docs., U.S. G.P.O., distributor]
Published: 1997
Place of publication: Rockville, MD; [Washington, D.C
Language: eng
Number of pages: 329
Subjects: Cocaine abuse -- Chemotherapy -- Congresses.; Cocaine abuse -- Treatment -- Congresses.; Clinical trials -- Congresses.; Cocaine -- congresses.; Substance-Related Disorders -- drug therapy -- congresses.; Substance Abuse Detection -- congresses.; Drug Evaluation -- congresses.; Clinical Trials -- congresses.
Notes: "Based on the papers from a technical review ... held on October 20-21, 1994"--p. ii.

Shipping list no.: 98-0092-P.

Includes bibliographical references.

Also available on the World Wide Web.
Table of contents: value: Goals and rationale for pharmacotherapeutic approach in treating cocaine dependence: insights from basic and clinical research; value: Overview of potential treatment medications for cocaine dependence; value: Methodologic recommendations for cocaine abuse clinical trials: a clinician-researcher's perspective; value: Management of clinical trials with new medications for cocaine dependence and abuse; value: Outcome measurement considerations: pharmacological treatments for substance abuse; value: Variability in treatment-seeking cocaine abusers: implications for clinical pharmacotherapy trials; value: Baseline assessment, study entry, and stabilization: double-blind clinical trials in drug dependence; value: Addiction severity index in clinical efficacy trials of medications for cocaine dependence; value: Cognitive-neuromotor assessment of substance abuse: focus on issues related to cocaine abuse treatment; value: Treatment effectiveness score as an outcome measure in clinical trials; value: Pharmacokinetics of cocaine: considerations when assessing cocaine use by urinalysis; value: Quantitative urine levels of cocaine and other substances of abuse; value: Use of quantitative urinalysis in monitoring cocaine use; value: Is quantitative urinalysis more sensitive?; value: Comparison of immunoassays for semiquantitative measurement of benzoylecgonine in urine; value: Appendix I: Workshop summary outcome measures and success criteria; value: Appendix II: Workshop summary clinical decision tree for cocaine addiction pharmacotherapy.